|Page (1) of 1 - 02/07/18||email article||print page|
(February 07, 2018)
BEIJING, Feb. 7, 2018 /PRNewswire/ -- Sinovac Biotech Ltd. (NASDAQ: SVA) ("Sinovac" or the "Company"), a leading provider of biopharmaceutical products in China, announced today that it held its 2017 Annual General Meeting of Shareholders on Tuesday, February 6, 2018 in Beijing, PRC. The Company is calculating the votes and evaluating the quorum and results of the shareholders meeting. The Company plans to announce the results of the shareholders meeting after completing this evaluation. Pending completion of this evaluation and in accordance with the Company's Articles of Incorporation and By-Laws and applicable law, the current members of the board will continue to serve until such time as their successors are validly elected. Sinovac has not authorized any third party to issue any press releases or other announcements regarding the results or status of the annual general meeting, and reserves all rights with respect thereto.
Sinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses on the research, development, manufacturing and commercialization of vaccines that protect against human infectious diseases. Sinovac's product portfolio includes vaccines against enterovirus71, or EV71, hepatitis A and B, seasonal influenza, H5N1 pandemic influenza (avian flu), H1N1 influenza (swine flu), and mumps. The EV71 vaccine, an innovative vaccine developed by Sinovac against hand foot and mouth disease caused by EV71, was commercialized in China in 2016. In 2009, Sinovac was the first company worldwide to receive approval for its H1N1 influenza vaccine, which it has supplied to the Chinese Government's vaccination campaign and stockpiling program. The Company is also the only supplier of the H5N1 pandemic influenza vaccine to the government stockpiling program. The Company is developing a number of new products including a Sabin-strain inactivated polio vaccine, pneumococcal polysaccharides vaccine, pneumococcal conjugate vaccine and varicella vaccine. Sinovac primarily sells its vaccines in China, while also exploring growth opportunities in international markets. The Company has exported select vaccines to over 10 countries in Asia and South America. For more information, please visit the Company's website at www.sinovac.com.
Safe Harbor Statement
This announcement may include certain statements that are not descriptions of historical facts, but are forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates" and similar statements. Forward-looking statements involve risks, uncertainties and other factors that could cause actual results to differ materially from those contained in any such statements.
Sinovac Biotech Ltd.
Email: [email protected]
Email: [email protected]
SOURCE Sinovac Biotech Ltd.
Copyright 2014 PR Newswire. All Rights Reserved
Related Keywords:USA, Inc.,Disease,Surgery,Childrens Health,Science,Medical,Biology,Other,
Related Sites: DMN Newswire , HTN - Health Technology Net
Related Newsletter: Tutorial Finder , Review Seeker , DMN Newswire Newsletter